Cytek Biosciences to Participate in Major Healthcare Conference
Fremont, California — Cytek Biosciences, Inc. (Nasdaq: CTKB), a pioneering company in cell analysis solutions, has announced its participation in the prestigious 43rd Annual J.P. Morgan Healthcare Conference. This event takes place in San Francisco, and Cytek looks forward to showcasing its cutting-edge technologies.
Presentation Details and Importance
On Thursday, January 16, Cytek management is scheduled to take the stage at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. The presentation promises to provide insights into Cytek’s advanced cell analysis tools, aimed at transforming cellular research. A live webcast will be available for all interested parties on their official website in the Investors section.
Overview of Cytek Biosciences
Cytek Biosciences specializes in cutting-edge cell analysis tools designed to enhance research capabilities across the globe. Their Full Spectrum Profiling™ (FSP™) technology harnesses the full power of fluorescent signals, which allows for high-resolution and high-sensitivity analysis. Cytek offers a variety of instruments including FSP instruments such as the Cytek Aurora™ and Northern Lights™ systems, and the Cytek Orion™ reagent system, as well as state-of-the-art sorting and detection technology.
Innovative Technologies Driving Research
By integrating various products like the Enhanced Small Particle™ (ESP™) detection tech, Cytek provides a comprehensive suite of solutions that are crucial for enhancing cell analysis research. The company’s flow cytometer products under the Amnis® and Guava® brands push the boundaries of current analytical capabilities, offering researchers the necessary tools to achieve unprecedented insights into cell biology.
Global Presence and Commitment
With headquarters in Fremont, California, Cytek maintains a strong global presence with offices and distribution channels worldwide. The company’s commitment to delivering innovative solutions is evident in its product offerings tailored for researchers. Although Cytek's products are primarily intended for research purposes, certain systems do find use in clinical settings in specific regions such as China and the European Union.
Transparency and Communication
To ensure transparent communication with stakeholders, Cytek actively utilizes a variety of channels. Besides making filings with the Securities and Exchange Commission (SEC), the company distributes information through its official website, LinkedIn page, and X (formerly Twitter) account. This ensures investors are well-informed about company updates, industry engagements, and all significant financial announcements.
Contact Information for Media and Investors
For media inquiries, Stephanie Olsen at Lages & Associates is the primary contact. She can be reached directly at (949) 453-8080 or via email. For investor-related inquiries, Paul Goodson is the Head of Investor Relations at Cytek Biosciences and is available for discussions regarding financial matters.
Frequently Asked Questions
What is the purpose of Cytek's participation in the conference?
The conference serves as a platform for Cytek to showcase its latest innovations in cell analysis solutions to potential investors and industry peers.
When is Cytek's presentation scheduled at the J.P. Morgan Conference?
Cytek's presentation is set for Thursday, January 16, at 8:15 a.m. Pacific Time.
What technologies does Cytek Biosciences specialize in?
Cytek specializes in cell analysis technology, particularly utilizing their Full Spectrum Profiling™ technology to enhance research capabilities.
How can investors stay updated on Cytek's activities?
Investors can stay informed through the company's website, LinkedIn page, and X account, in addition to following SEC filings and public announcements.
Are Cytek’s products used in clinical settings?
Yes, certain products like the Northern Lights-CLC system are available for clinical use in specific regions, such as China and the European Union.
